LEBANON – OptiFreight Logistics, a CAH company, has partnered with Journey Biosciences, Inc. to improve control and visibility across all modes of transportation to enhance point of care diabetes care.
This agreement will bring Journey Biosciences’ pivotal, first-of-its-kind NaviDKD (Diabetic Kidney Disease) medical diagnostics screening technology to the point-of-care, where innovative testing and risk assessment will take place using highly advanced proprietary algorithms.
Journey Biosciences’ mission is to fundamentally improve diabetes care by providing diagnostic screening tools to health care professionals and people with diabetes to proactively manage and prevent high risk complications associated with DKD.
“For years, diabetes has been a reactive conversation,” said Adam Graybill, president and CEO of Journey Biosciences. “Healthcare providers have been challenged to react to what has already happened or is happening real-time, including past test results, scores and levels.”
OptiFreight Logistics on the other hand provides comprehensive logistics management to the healthcare industry.
In this partnership, OptiFreight Logistics will provide customized logistics solutions with increased visibility for critical healthcare deliveries as Journey Biosciences expands across the industry to improve the diagnostic screening process.
“We believe in this mission and are confident our relationship with Journey Biosciences will strengthen the fight against a disease that has unique needs and, unfortunately, touches so many.”
According to Research and Markets, the global healthcare logistics market is expected to grow by US$67.73 billion at an 11 percent CAGR during the forecast period 2021-2025.
Increased global pharmaceutical sales, expanding government initiatives, and increased seaborne pharmaceutical transportation are some of the factors driving the growth of this market. As a result, Cardinal Health’s collaboration is well-timed.
Cardinal Health Canada, the company’s wholly owned subsidiary, recently announced an employee vaccination requirement policy in September, as part of its ongoing efforts to protect employees, customers, and the Canadian Healthcare system from COVID-19.
Cardinal Health and IRE EliT, the radiopharmaceutical subsidiary of IRE Group, collaborated in August to increase patient access to novel radiopharmaceuticals for Positron Emission Tomography (PET) imaging, in order to meet the growing demand for Ga-68 labeled radiopharmaceuticals.